159 related articles for article (PubMed ID: 29387237)
1. Bioinformatics analysis of gene expression alterations conferring drug resistance in tumor samples from melanoma patients with EGFR-activating
Yu Y; Wang X; Li Q; Zhang M; Xu P; Chen Y; Yan Y; Zhang L
Oncol Lett; 2018 Jan; 15(1):635-641. PubMed ID: 29387237
[TBL] [Abstract][Full Text] [Related]
2. In-depth genomic data analyses revealed complex transcriptional and epigenetic dysregulations of BRAFV600E in melanoma.
Guo X; Xu Y; Zhao Z
Mol Cancer; 2015 Mar; 14():60. PubMed ID: 25890285
[TBL] [Abstract][Full Text] [Related]
3. EGFR Pathway-Based Gene Signatures of Druggable Gene Mutations in Melanoma, Breast, Lung, and Thyroid Cancers.
Raevskiy M; Sorokin M; Vladimirova U; Suntsova M; Efimov V; Garazha A; Drobyshev A; Moisseev A; Rumiantsev P; Li X; Buzdin A
Biochemistry (Mosc); 2021 Nov; 86(11):1477-1488. PubMed ID: 34906047
[TBL] [Abstract][Full Text] [Related]
4. Mutations in BRAF codons 594 and 596 predict good prognosis in melanoma.
Wu X; Yan J; Dai J; Ma M; Tang H; Yu J; Xu T; Yu H; Si L; Chi Z; Sheng X; Cui C; Kong Y; Guo J
Oncol Lett; 2017 Sep; 14(3):3601-3605. PubMed ID: 28927118
[TBL] [Abstract][Full Text] [Related]
5. Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer.
Okimoto RA; Lin L; Olivas V; Chan E; Markegard E; Rymar A; Neel D; Chen X; Hemmati G; Bollag G; Bivona TG
Proc Natl Acad Sci U S A; 2016 Nov; 113(47):13456-13461. PubMed ID: 27834212
[TBL] [Abstract][Full Text] [Related]
6. MAP kinase activity supported by BRAF (V600E) mutation rather than gene amplification is associated with ETV1 expression in melanoma brain metastases.
Birner P; Berghoff AS; Dinhof C; Pirker C; Capper D; Schoppmann SF; Petzelbauer P; von Deimling A; Berger W; Preusser M
Arch Dermatol Res; 2014 Dec; 306(10):873-84. PubMed ID: 25073704
[TBL] [Abstract][Full Text] [Related]
7. Distinct dependencies on receptor tyrosine kinases in the regulation of MAPK signaling between BRAF V600E and non-V600E mutant lung cancers.
Kotani H; Adachi Y; Kitai H; Tomida S; Bando H; Faber AC; Yoshino T; Voon DC; Yano S; Ebi H
Oncogene; 2018 Mar; 37(13):1775-1787. PubMed ID: 29348459
[TBL] [Abstract][Full Text] [Related]
8. Hybrid Capture-Based Genomic Profiling Identifies BRAF V600 and Non-V600 Alterations in Melanoma Samples Negative by Prior Testing.
Boussemart L; Nelson A; Wong M; Ross JS; Sosman J; Mehnert J; Daniels G; Kendra K; Ali SM; Miller VA; Schrock AB
Oncologist; 2019 May; 24(5):657-663. PubMed ID: 30683711
[TBL] [Abstract][Full Text] [Related]
9. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
[TBL] [Abstract][Full Text] [Related]
10. Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial.
Chen G; McQuade JL; Panka DJ; Hudgens CW; Amin-Mansour A; Mu XJ; Bahl S; Jané-Valbuena J; Wani KM; Reuben A; Creasy CA; Jiang H; Cooper ZA; Roszik J; Bassett RL; Joon AY; Simpson LM; Mouton RD; Glitza IC; Patel SP; Hwu WJ; Amaria RN; Diab A; Hwu P; Lazar AJ; Wargo JA; Garraway LA; Tetzlaff MT; Sullivan RJ; Kim KB; Davies MA
JAMA Oncol; 2016 Aug; 2(8):1056-64. PubMed ID: 27124486
[TBL] [Abstract][Full Text] [Related]
11. KIT Suppresses BRAF
Neiswender JV; Kortum RL; Bourque C; Kasheta M; Zon LI; Morrison DK; Ceol CJ
Cancer Res; 2017 Nov; 77(21):5820-5830. PubMed ID: 28947418
[TBL] [Abstract][Full Text] [Related]
12. Targeted Therapy for Colorectal Cancers With Non-V600 BRAF Mutations: Perspectives for Precision Oncology.
Dankner M
JCO Precis Oncol; 2018 Nov; 2():1-12. PubMed ID: 35135170
[TBL] [Abstract][Full Text] [Related]
13. Response to Anti-EGFR Therapy in Patients with BRAF non-V600-Mutant Metastatic Colorectal Cancer.
Yaeger R; Kotani D; Mondaca S; Parikh AR; Bando H; Van Seventer EE; Taniguchi H; Zhao H; Thant CN; de Stanchina E; Rosen N; Corcoran RB; Yoshino T; Yao Z; Ebi H
Clin Cancer Res; 2019 Dec; 25(23):7089-7097. PubMed ID: 31515458
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological features and clinical outcomes associated with TP53 and BRAF
Kim DW; Haydu LE; Joon AY; Bassett RL; Siroy AE; Tetzlaff MT; Routbort MJ; Amaria RN; Wargo JA; McQuade JL; Kemnade J; Hwu P; Woodman SE; Roszik J; Kim KB; Gershenwald JE; Lazar AJ; Davies MA
Cancer; 2017 Apr; 123(8):1372-1381. PubMed ID: 27911979
[TBL] [Abstract][Full Text] [Related]
15.
Kulkarni A; Al-Hraishawi H; Simhadri S; Hirshfield KM; Chen S; Pine S; Jeyamohan C; Sokol L; Ali S; Teo ML; White E; Rodriguez-Rodriguez L; Mehnert JM; Ganesan S
Clin Cancer Res; 2017 Sep; 23(18):5631-5638. PubMed ID: 28539463
[No Abstract] [Full Text] [Related]
16. Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis.
Willmore-Payne C; Holden JA; Tripp S; Layfield LJ
Hum Pathol; 2005 May; 36(5):486-93. PubMed ID: 15948115
[TBL] [Abstract][Full Text] [Related]
17. Molecular therapeutic advances in personalized therapy of melanoma and non-small cell lung cancer.
Kelleher FC; Solomon B; McArthur GA
J Pers Med; 2012 Apr; 2(2):35-49. PubMed ID: 25562798
[TBL] [Abstract][Full Text] [Related]
18. Activated MEK cooperates with Cdkn2a and Pten loss to promote the development and maintenance of melanoma.
Yang H; Kircher DA; Kim KH; Grossmann AH; VanBrocklin MW; Holmen SL; Robinson JP
Oncogene; 2017 Jul; 36(27):3842-3851. PubMed ID: 28263969
[TBL] [Abstract][Full Text] [Related]
19. A comparison of immunohistochemical and molecular methods used for analyzing the BRAF V600E gene mutation in malignant melanoma in Taiwan.
Huang WK; Kuo TT; Wu CE; Cheng HY; Hsieh CH; Hsieh JJ; Shen YC; Hou MM; Hsu T; Chang JW
Asia Pac J Clin Oncol; 2016 Dec; 12(4):403-408. PubMed ID: 27488807
[TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.
Trunzer K; Pavlick AC; Schuchter L; Gonzalez R; McArthur GA; Hutson TE; Moschos SJ; Flaherty KT; Kim KB; Weber JS; Hersey P; Long GV; Lawrence D; Ott PA; Amaravadi RK; Lewis KD; Puzanov I; Lo RS; Koehler A; Kockx M; Spleiss O; Schell-Steven A; Gilbert HN; Cockey L; Bollag G; Lee RJ; Joe AK; Sosman JA; Ribas A
J Clin Oncol; 2013 May; 31(14):1767-74. PubMed ID: 23569304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]